This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
54
The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
Novo Nordisk Investigational Site
Neuss, Germany
Area under the glucose infusion rate curve during one dosing interval at steady state
Time frame: 0-24 hours (derived on treatment days 6, 9 and 12)
Area under the NN1250 concentration-time curve during one dosing interval at steady state
Time frame: 0-24 hours (derived on treatment days 6, 9 and 12)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.